A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Cediranib (Primary) ; Sunitinib (Primary)
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- 05 Aug 2017 Planned End Date changed from 28 Apr 2018 to 15 Jun 2018.
- 04 May 2017 Planned End Date changed from 28 Apr 2017 to 28 Apr 2018.
- 04 May 2017 Planned primary completion date changed from 28 Apr 2017 to 28 Apr 2018.